SELLAS Life Sciences Group Inc sell BiotechBee
Start price
04:31
/
90%
€8.66
Target price
30.04.28
€1.00
Performance (%)
-0.23%
Price
13:28
€8.78
Summary
This prediction is currently active. The SELL prediction by BiotechBee for SELLAS Life Sciences Group Inc is nearly unchanged. This prediction currently runs until 30.04.28. The prediction end date can be changed by BiotechBee at any time. BiotechBee has 90% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w |
|---|---|
| SELLAS Life Sciences Group Inc | -0.23% |
| iShares Core DAX® | 2.591% |
| iShares Nasdaq 100 | -0.915% |
| iShares Nikkei 225® | 0.145% |
| iShares S&P 500 | -0.367% |
According to BiotechBee what are the pros and cons of SELLAS Life Sciences Group Inc for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by BiotechBee for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Stopped prediction by BiotechBee for SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€1.09
08.09.24
08.09.24
€1.50
30.04.27
30.04.27
-21.73%
14.12.24
14.12.24
Could be very worthwhile Investment >20% year
